ALKERMES PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.05 USD | -0.87% |
|
0.00% | -13.30% |
| May. 02 | UBS Adjusts Price Target on Alkermes to $21 From $23, Maintains Sell Rating | MT |
| May. 01 | Alkermes's Q1 Earnings, Revenue Grow But Miss Street View | MT |
Presenter SpeechChris Shibutani (Analysts)So let's get underway. Good afternoon, everybody. We...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Alkermes plc is a global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
Calendar
2024-05-31
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
24.05
USD
Average target price
33.82
USD
Spread / Average Target
+40.62%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.30% | 4.07B | |
| +17.96% | 44.96B | |
| +48.77% | 41.85B | |
| +1.17% | 42.65B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- ALKS Stock
- News Alkermes plc
- Transcript : Alkermes plc Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-15-2022 02